[1]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151-152155.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Journal of Medical Information,2019,32(18):151-152155.[doi:10.3969/j.issn.1006-1959.2019.18.052]
点击复制

拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年18期
页码:
151-152155
栏目:
药物与临床
出版日期:
2019-09-15

文章信息/Info

Title:
Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis
文章编号:
1006-1959（2019）18-0151-03
作者:
陈新华
江西省吉安市吉水县人民医院感染科，江西 吉安 331600
Author(s):
CHEN Xin-hua
Department of Infectious Diseases,People's Hospital of Jishui County,Ji'an 331600,Jiangxi,China
关键词:
乙型肝炎相关肝硬化; 拉米夫定; 恩替卡韦; 长期疗效; 安全性
Keywords:
Key words：Hepatitis B-associated cirrhosis; Lamivudine; Entecavir; Long-term efficacy; safety
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2019.18.052
文献标志码:
A
摘要:
目的 探讨乙型肝炎相关肝硬化采用拉米夫定联合恩替卡韦治疗的长期疗效与安全性。方法 选取2017年6月~2019年1月我院收治的150例乙型肝炎相关肝硬化患者，随机分为对照组和观察组，每组75例。对照组采用恩替卡韦治疗，观察组采用拉米夫定联合恩替卡韦治疗。采用荧光定量聚合酶链反应法测量患者治疗6个月及治疗12个月的乙肝病毒基因转阴率，评估患者临床总有效率，比较谷丙转氨酶（ALT）、谷草转氨酶（AST）及总胆红素（TBIL）水平，观察并发症发生情况。结果 观察组治疗6个月及治疗12个月的乙肝病毒基因转阴率分别为60.00%和98.67%，均高于对照组的45.33%和85.33%，差异具有统计学意义（P＜0.05）；治疗后，观察组的治疗有效率高于对照组（96.00% vs 81.33%），差异具有统计学意义（P＜0.05）；治疗后，两组患者的ALT、AST及TBIL水平低于治疗前，且观察组的ALT、AST及TBIL水平较对照组下降幅度更大（P＜0.05）；观察组患者并发症发生率与对照组比较（4.00% vs 2.67%），差异无统计学意义（P＞0.05）。结论 针对乙型肝炎相关肝硬化患者，采用拉米夫定联合恩替卡韦治疗长期疗效更佳，改善肝功能，安全有效。
Abstract:
Abstract：Objective To investigate the long-term efficacy and safety of lamivudine combined with entecavir in the treatment of patients with hepatitis B-related cirrhosis. Methods A total of 150 patients with hepatitis B-related cirrhosis admitted to our hospital from June 2017 to January 2019 were randomly divided into control group and observation group, with 75 cases in each group. The control group was treated with entecavir alone, and the observation group was treated with lamivudine plus entecavir. Fluorescence quantitative polymerase chain reaction (PCR) was used to measure the rate of hepatitis B virus gene transfusion in patients treated for 6 months and 12 months, and the total clinical effectiveness was evaluated. The alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) was compared, the occurrence of complications was observed.Results The conversion rate of hepatitis B virus gene in the observation group was 60.00% and 98.67% for 6 months and 12 months, respectively, which were higher than that of the control group 45.33% and 85.33%, the difference was statistically significant (P<0.05); After treatment, the effective rate of the observation group was higher than that of the control group (96.00% vs 81.33%), the difference was statistically significant (P<0.05). After treatment, the ALT, AST and TBIL levels in the two groups were lower than the treatment.The ALT, AST and TBIL levels in the observation group were more significant than those in the control group (P<0.05). The complication rate in the observation group was compared with the control group (4.00% vs 2.67%),the difference was not statistically significant (P>0.05). Conclusion For patients with hepatitis B-related cirrhosis, lamivudine combined with entecavir has better long-term efficacy and improved liver function, which is safe and effective.

参考文献/References:

[1]李正康,张鑫强,刘素玲,等.凝血四项指标和肿瘤标志物在乙型肝炎病毒感染相关肝硬化和原发性肝癌中的诊断价值[J].中国实验诊断学,2016,89(12):2061-2065. [2]张良东,刘杰,任晓娟,等.正常肝脏与乙型肝炎肝硬化及乙型肝炎病毒相关性肝癌组织中miRNA表达谱差异[J].中华医院感染学杂志,2016,114(4):115-116. [3]陈锐俊,薛梅,高燕灵,等.乙型肝炎相关肝硬化肝癌和无肝硬化肝癌患者围术期情况及肝衰竭危险因素分析[J].河北医科大学学报,2018,39(6):640-644. [4]王铁征,武聚山,孟凡坤,等.瞬时弹性测定对无创诊断早期乙型肝炎相关肝硬化的价值评价[J].首都医科大学学报,2017,38(2):299-303. [5]茅益民,尤红,贾继东.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理[J].国际消化病杂志,2016,56(2):138-148. [6]陈柳莹,尹珊,王十锦,等.简化MELD评分可准确区分乙型肝炎相关肝硬化急性失代偿患者为不同短期预后群体[J].胃肠病学,2016,21(5):263-267. [7]康瑜,陈建芳,曾甜.慢性乙型肝炎肝硬化患者Th22细胞和IL-22的表达及意义[J].免疫学杂志,2017,89(2):147-151. [8]李新文,范玉琛,邢延清,等.阿德福韦酯联合拉米夫定或恩替卡韦治疗慢性乙型肝炎和肝硬化出现肾损害后的处理[J].中国临床医生杂志,2019,47(5):542-546. [9]张鑫岩,黄馨莹,于晓松.恩替卡韦单药与拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化疗效对比的Meta分析[J].肝脏,2019,24(4):392-398.

相似文献/References:

[1]赵 锐.拉米夫定联合替诺福韦与依非韦伦治疗艾滋病的临床效果及对肝功能的影响[J].医学信息,2023,36(15):124.[doi:10.3969/j.issn.1006-1959.2023.15.025]
　ZHAO Rui.Clinical Effect of Lamivudine Combined with Tenofovirdisoproxil and Efavirenz in the Treatment of AIDS and its Effect on Liver Function[J].Journal of Medical Information,2023,36(18):124.[doi:10.3969/j.issn.1006-1959.2023.15.025]

更新日期/Last Update: 2019-09-15